PTIX vs. TENX, YMTX, ADIL, CLVR, TRVN, CVKD, CANF, EFTR, GRAY, and IBIO
Should you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Tenax Therapeutics (TENX), Yumanity Therapeutics (YMTX), Adial Pharmaceuticals (ADIL), Clever Leaves (CLVR), Trevena (TRVN), Cadrenal Therapeutics (CVKD), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Graybug Vision (GRAY), and iBio (IBIO). These companies are all part of the "pharmaceutical preparations" industry.
Protagenic Therapeutics (NASDAQ:PTIX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.
In the previous week, Tenax Therapeutics had 1 more articles in the media than Protagenic Therapeutics. MarketBeat recorded 1 mentions for Tenax Therapeutics and 0 mentions for Protagenic Therapeutics. Tenax Therapeutics' average media sentiment score of 1.00 beat Protagenic Therapeutics' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.
8.0% of Protagenic Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 37.0% of Protagenic Therapeutics shares are held by insiders. Comparatively, 1.9% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Protagenic Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500.
Tenax Therapeutics has a consensus price target of $480.00, suggesting a potential upside of 13,693.10%. Given Tenax Therapeutics' higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Protagenic Therapeutics.
Tenax Therapeutics received 140 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users.
Tenax Therapeutics' return on equity of -65.79% beat Protagenic Therapeutics' return on equity.
Summary
Tenax Therapeutics beats Protagenic Therapeutics on 8 of the 11 factors compared between the two stocks.
Get Protagenic Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protagenic Therapeutics Competitors List
Related Companies and Tools
